Related Experiment Video
Updated: Jun 28, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Role of thalidomide in previously untreated patients with multiple myeloma
Pellegrino Musto1, Fiorella D'Auria, Giuseppe Pietrantuono
1Unit of Hematology and Stem Cell Transplantation, IRCCS-CROB, Oncology Referral Center of Basilicata, Rionero in Vulture, Pz, Italy. p.musto@crob.it
Abstract:
Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Teratogenicity
Drugs that Stabilize Microtubules
